An observational, prospective study to assess the efficacy and safety of Adalloce in patients with Rheumatoid Arthritis (RA) and Ankylosing Spondylitis (AS)

Yuhan0 个研究点目标入组 1,000 人开始时间: 待定最近更新: 2024年3月4日

适应症

试验速览

暂无简介。

•1. Men and women between the ages of over 19 and under 75 at the time of consent
•2. Patients diagnosed with RA or AS at least 3 months prior to the study registration
•3. Patients who are scheduled to be prescribed Adalloce according to the doctor's opinions
•4. Patients who have never received Adalloce
•5. Patients who voluntarily gave their written consent after being sufficiently explained about the purpose and contents of this study

•1. Patients with hypersensitivity to this drug or its components
•2. Patients with active tuberculosis or other severe infection such as sepsis or opportunistic infection
•3. Patients with moderate to severe heart failure (NYHA class III/IV)
•4. Patients who are judged to be inappropriate for Adalloce administration according to the approved conditions
•5. Patients who are not suitable for participation in this study according to the judgment of the investigator
•6. Patients participating in other drug clinical trials (Adalloce PMS participants cannot participate in this study)

发起方